FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987327992> ?p ?o ?g. }

• W2987327992 endingPage "4125" @default.
• W2987327992 startingPage "4125" @default.
• W2987327992 abstract "Introduction: Primary central nervous system lymphoma (PCNSL) is a rare and aggressive primary brain tumor confined to the brain, eyes, and cerebrospinal fluid. Over the past few decades, prognosis for PCNSL has significantly improved due to the standard use of high dose methotrexate (MTX) containing treatment regimens. However, it remains unclear if the number of MTX doses and the addition of rituximab has an impact on clinical outcomes. The recent HOVON 105/ALLG NHL 24 study questioned the role of rituximab in the first line setting when combined with a MTX based polychemotherapy using only 4 doses of MTX and 6 doses of rituximab. Over the last 30 years, standard of care at Memorial Sloan Kettering Cancer Center (MSKCC) has evolved, allowing the comparison of patients receiving different numbers of MTX doses and those treated with and without rituximab. The purpose of this study was to describe clinical outcomes based on standard of care treatment changes. Methods: This single-center retrospective IRB approved study at MSKCC included patients with immunocompetent PCNSL, age ≥18 years and diagnosed between 1/1983-11/2017. Patients were identified through a departmental database and electronic medical record. The primary objective was to describe overall survival (OS) based on common prognostic markers such as age, KPS, MSKCC prognostic score class (RPA I- III), use of rituximab, and number of methotrexate cycles. Overall survival was calculated from the date of diagnosis to death or last follow-up using Kaplan-Meier methodology. When examining effect of MTX on OS, OS was calculated from date of last MTX cycle until death or last follow-up. Univariable and multivariable analysis for prognostic factors were analyzed using Cox proportional hazards regression. Results: Five hundred and forty-six patients with newly diagnosed PCNSL were identified. Median age at diagnosis was 62 (range 19 to 90), median KPS was 70 (range 10 to 100), and 282 (52%) were men. In total, 472 patients (86.4%) received high dose MTX. Of 460 with known number of MTX cycles, 95 (20.7%) received 1-4 cycles and 365 (79.3%) received ≥5 cycles (5 cycles: 189, 41.1%, 6 cycles: 24, 5.2%, 7 cycles: 74, 16.1%, 8+ cycles: 78, 17%). Rituximab was given to 231 (42.3%). Three hundred and ten (56.8%) patients, treated before 2006, had been reported previously (historic cohort) and 236 (43.2%) served as contemporary cohort. Median OS of the entire population was 4.7 years (95% CI: 3.8-5.7); 3.3 years (95% CI: 2.8-4.1) in the historic and 8.1 years (95% CI: 6.6-no upper limit) in the contemporary cohort. Five-year OS was 40.3% (95% CI: 35.1-46.2) for the historical cohort and 61.8% (95% CI: 55.0-69.5) for the contemporary cohort. Median OS in the contemporary cohort improved in all RPA classes in comparison to patients treated before 2006 (RPA I: not yet reached vs 9.2 years; RPA II: 7.6 years vs 3.5 years; RPA III 2.8 years vs 1.0 year) (Fig. 1). For the historical cohort compared to the contemporary cohort, five-year OS changed from 62.8% to 91.0% in RPA I, 42.0% to 63.0% in RPA II, and 16.3% to 36.9% in RPA III. Patients receiving ≥ 6 cycles of MTX had a better clinical outcome (median OS from last MTX cycle: 7.8 years versus 4.3 years; HR 0.68 (95% CI (0.51 - 0.91), p=0.0085) on multivariable analysis adjusted for age, KPS, sex, RPA classes Additionally, the stratification of rituximab further elucidated the association between MTX cycles and OS, such that in patients receiving rituximab, those treated with ≥ 6 cycles of MTX experienced longer median OS compared to patients receiving &lt; 6 cycles of MTX (13.0 years vs 9.4 years, p=0.001). Furthermore, in patients receiving ≥ 6 cycles of MTX, there was a survival benefit seen in patients who received rituximab compared to those who did not receive rituximab (13.02 years vs 1.61 years, p&lt;000.1) (Fig.2). Conclusions: Overall survival for newly diagnosed PCNSL has improved significantly over the last few decades regardless of age, KPS, RPA class. Patients seem to benefit with the addition of rituximab and when receiving 6 or more cycles of MTX. Disclosures Grommes: BTG: Consultancy; Kite: Consultancy; Squipps: Speakers Bureau." @default.
• W2987327992 created "2019-11-22" @default.
• W2987327992 creator A5002965160 @default.
• W2987327992 creator A5008761191 @default.
• W2987327992 creator A5017631516 @default.
• W2987327992 creator A5027810181 @default.
• W2987327992 creator A5039932065 @default.
• W2987327992 creator A5070287901 @default.
• W2987327992 creator A5074441104 @default.
• W2987327992 date "2019-11-13" @default.
• W2987327992 modified "2023-10-16" @default.
• W2987327992 title "Increased Number of High Dose Methotrexate Cycles and the Addition of Rituximab Is Associated with Better Outcomes in a Large Primary CNSL Cohort" @default.
• W2987327992 doi "https://doi.org/10.1182/blood-2019-130349" @default.
• W2987327992 hasPublicationYear "2019" @default.
• W2987327992 type Work @default.
• W2987327992 sameAs 2987327992 @default.
• W2987327992 citedByCount "0" @default.
• W2987327992 crossrefType "journal-article" @default.
• W2987327992 hasAuthorship W2987327992A5002965160 @default.
• W2987327992 hasAuthorship W2987327992A5008761191 @default.
• W2987327992 hasAuthorship W2987327992A5017631516 @default.
• W2987327992 hasAuthorship W2987327992A5027810181 @default.
• W2987327992 hasAuthorship W2987327992A5039932065 @default.
• W2987327992 hasAuthorship W2987327992A5070287901 @default.
• W2987327992 hasAuthorship W2987327992A5074441104 @default.
• W2987327992 hasConcept C126322002 @default.
• W2987327992 hasConcept C141071460 @default.
• W2987327992 hasConcept C143998085 @default.
• W2987327992 hasConcept C167135981 @default.
• W2987327992 hasConcept C2776694085 @default.
• W2987327992 hasConcept C2776907518 @default.
• W2987327992 hasConcept C2779338263 @default.
• W2987327992 hasConcept C2780653079 @default.
• W2987327992 hasConcept C2781059491 @default.
• W2987327992 hasConcept C2781173314 @default.
• W2987327992 hasConcept C71924100 @default.
• W2987327992 hasConcept C72563966 @default.
• W2987327992 hasConceptScore W2987327992C126322002 @default.
• W2987327992 hasConceptScore W2987327992C141071460 @default.
• W2987327992 hasConceptScore W2987327992C143998085 @default.
• W2987327992 hasConceptScore W2987327992C167135981 @default.
• W2987327992 hasConceptScore W2987327992C2776694085 @default.
• W2987327992 hasConceptScore W2987327992C2776907518 @default.
• W2987327992 hasConceptScore W2987327992C2779338263 @default.
• W2987327992 hasConceptScore W2987327992C2780653079 @default.
• W2987327992 hasConceptScore W2987327992C2781059491 @default.
• W2987327992 hasConceptScore W2987327992C2781173314 @default.
• W2987327992 hasConceptScore W2987327992C71924100 @default.
• W2987327992 hasConceptScore W2987327992C72563966 @default.
• W2987327992 hasIssue "Supplement_1" @default.
• W2987327992 hasLocation W29873279921 @default.
• W2987327992 hasOpenAccess W2987327992 @default.
• W2987327992 hasPrimaryLocation W29873279921 @default.
• W2987327992 hasRelatedWork W2108492034 @default.
• W2987327992 hasRelatedWork W2136426334 @default.
• W2987327992 hasRelatedWork W2516167102 @default.
• W2987327992 hasRelatedWork W2889721425 @default.
• W2987327992 hasRelatedWork W2907729024 @default.
• W2987327992 hasRelatedWork W2987327992 @default.
• W2987327992 hasRelatedWork W3107525433 @default.
• W2987327992 hasRelatedWork W3134284752 @default.
• W2987327992 hasRelatedWork W4248707236 @default.
• W2987327992 hasRelatedWork W4323982184 @default.
• W2987327992 hasVolume "134" @default.
• W2987327992 isParatext "false" @default.
• W2987327992 isRetracted "false" @default.
• W2987327992 magId "2987327992" @default.
• W2987327992 workType "article" @default.